Echinodone



Compound IDCDAMM01800
Common nameEchinodone
IUPAC name[2,8,10,14,18,18-hexamethyl-6-(2-methylprop-1-enyl)-17-oxo-5-oxapentacyclo[11.8.0.02,10.04,9.014,19]henicos-1(13)-en-7-yl] acetate
Molecular formulaC32H48O4

Experimental data

Retention time15.6
Adduct[M+NH4]+
Actual mz514.39
Theoretical mz514.389
Error1.32
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.584

Identifiers and class information

Inchi keyACPQHJVBMJBRJO-BZZCOUAPNA-N
SmilesO=C(OC1C(OC2CC3(C4=C(CCC3(C)C2C1C)C5(C)CCC(=O)C(C)(C)C5CC4)C)C=C(C)C)C
SuperclassLipids and lipid-like molecules
ClassPrenol lipids

Pharmacokinetic properties

Number of descriptor values(#stars)2
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)2
Number of reactive functional groups (#rtvFG)1
Predicted central nervous system activity (CNS)0
Molecular weight (mol_MW)496.729
Computed dipole moment(dipole)2.322
Total solvent accessible surface area (SASA)793.053
Hydrophobic component of SASA (FOSA)706.219
Hydrophilic component of SASA (FISA)81.831
Pie component of the SASA (PISA)5.002
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1580.72
Number of hydrogen bond donors (donorHB)0
Number of hydrogen bond acceptors (accptHB)5.7
Free energy of solvation of dipole (dip^2/V)0.0034112
Index of cohesive interaction in solids (ACxDN^.5/SA)0
Globularity descriptor (glob)0.827497
Predicted polarizability in cubic angstroms (QPpolrz)55.87
Predicted hexadecane/gas partition coefficient (QPlogPC16)13.358
Predicted octanol/gas partition coefficient (QPlogPoct)21.494
Predicted water/gas partition coefficient (QPlogPw)7.392
Predicted octanol/water partition coefficient (QPlogPo/w)6.271
Predicted aqueous solubility (QPlogS)-7.935
Conformation-independent predicted aqueous solubility (CIQPlogS)-7.135
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-4.347
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)1659.18
Predicted brain/blood partition coefficient (QPlogBB)-0.354
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)855.125
Predicted skin permeability, log Kp (QPlogKp)-2.818
PM3 calculated ionization potential (IP(ev))9.295
PM3 calculated electron affinity (EA(eV))-0.784
Number of likely metabolic reactions (#metab)7
Prediction of binding to human serum albumin (QPlogKhsa)1.597
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)100
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)65.846
Number of nitrogen and oxygen atoms (#NandO)4
Number of violations of Lipinski’s rule of five (RuleOfFive)1
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P35228NOS2Nitric oxide synthase, inducibleT02703SwissTargetPrediction
P17612PRKACAcAMP-dependent protein kinase alpha-catalytic subunitT12808SwissTargetPrediction
P49356FNTBFarnesyl protein transferaseT13127SwissTargetPrediction
P05771PRKCBProtein kinase C betaT40276SwissTargetPrediction
P50579METAP2Methionine aminopeptidase 2T75596SwissTargetPrediction
P25024CXCR1Interleukin-8 receptor AT00884SwissTargetPrediction
P55085F2RL1Proteinase-activated receptor 2T62841SwissTargetPrediction
P01584IL1BInterleukin-1 betaT42000SwissTargetPrediction
Q13526PIN1Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1T16308SEA
P05129PRKCGProtein kinase C gammaT47107SwissTargetPrediction
P41252IARSIsoleucyl-tRNA synthetaseT46515SwissTargetPrediction

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T02703DI0083Chronic kidney disease[ICD-11: GB61]P35228NOS2
T02703DI0320Osteoarthritis[ICD-11: FA00-FA05]P35228NOS2
T02703DI0375Sepsis[ICD-11: 1G40-1G41]P35228NOS2
T02703DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P35228NOS2
T12808DI0279Muscular atrophy[ICD-11: 8B61]P17612PRKACA
T13127DI0342Premature ageing appearance[ICD-11: LD2B]P49356FNTB
T40276DI0123Diffuse large B-cell lymphoma[ICD-11: 2A81]P05771PRKCB
T40276DI0241Lymphoma[ICD-11: 2A80-2A86]P05771PRKCB
T40276DI0245Malignant haematopoietic neoplasm[ICD-11: 2B33]P05771PRKCB
T75596DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P50579METAP2
T00884DI0324Pain[ICD-11: MG30-MG3Z]P25024CXCR1
T62841DI0087Chronic pain[ICD-11: MG30]P55085F2RL1
T42000DI0267Mineral excesses[ICD-11: 5B91]P01584IL1B
T42000DI0269Monogenic autoinflammatory syndrome[ICD-11: 4A60]P01584IL1B
T42000DI0320Osteoarthritis[ICD-11: FA00-FA05]P01584IL1B
T42000DI0366Rheumatoid arthritis[ICD-11: FA20]P01584IL1B
T16308DI0238Lung cancer[ICD-11: 2C25]Q13526PIN1
T47107DI0012Acute myeloid leukaemia[ICD-11: 2A60]P05129PRKCG
T47107DI0248Mastocytosis[ICD-11: 2A21]P05129PRKCG

Copyright © 2025